A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Eli Lilly and Company
Location: International Diabetes Center
Purpose of study: This study will test for differences in blood sugars for people with type 2 diabetes who are using one of two different medications in addition to their usual diabetes medications. One is the investigational study medication, the other is a drug that is FDA approved for use with type 2 diabetes. Participants will be randomly assigned to receive one of these two medications. This study is designed for people with type 2 diabetes who are having trouble controlling their blood sugars with their current treatment. Past research with the study medication has shown an improvement in A1c and body weight.
Inclusion Criteria:
– The study is accepting males and females ages 18 and older who:
– Have type 2 diabetes
– Are taking only pills for treating their diabetes
– Have an A1C between 7.0-10.5%
– Meet other study specific requirements
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Flair – Fuzzy Logic Automated Insulin Regulation: A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs PID + Fuzzy Logic) in Individuals with Type 1 Diabetes (The FLAIR Study)
Principal Investigators: Richard Bergenstal, MD; Anders Carlson, MD; Amy Criego, MD
Study sponsor: National Institutes of Health
Location: International Diabetes Center
Purpose of study: This study will test two different types of insulin delivery systems known as automated insulin delivery (AID) systems. AID systems are designed to help people with type 1 diabetes control their blood sugar (glucose) levels. An AID system is
made up of three parts: (1) a continuous glucose monitor (CGM) that measures glucose levels; (2) an insulin pump that delivers insulin; and (3) a computer program on the insulin pump that can tell the pump how much insulin to give you.
Inclusion Criteria:
The study is accepting males and females ages 14-29 years old who:
Have had type 1 diabetes for at least a year
Have a hemoglobin A1c between 7-11%
Are willing and able to upload glucose and pump data between visits
Meet other study specific requirements
Involvement in the trial will include:
Participation in the study for about 8-10 months
Using the study pumps and CGM provided. Glucose meter and strips will be
provided.
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Multi-Center Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System at Home (304)
Principal Investigator: Anders Carlson, MD; Amy Criego, MD
Study Sponsor: Medtronic
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to look at the safety and effectiveness of the hybrid closed loop (HCL) insulin pump system, MiniMed 670G, used in a home setting by people with type 1 diabetes. This system consists of an insulin pump, a new generation of Medtronic glucose sensor, a new insertion device for the sensor, and a new glucose meter. The HCL uses continuous glucose sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 1 diabetes. The MiniMed 670G has recently been approved by the FDA for use in the United States for ages 14-80, and use in ages 2-13 in this study will be considered investigational.
Inclusion Criteria:
The study is currently accepting males and females ages 7-80 who:
– Have had type 1 diabetes for 3 months or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
– Meet other study specific requirements.
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Post Approval Study for Non-Adjunctive Use of Dexcom G5® CGM System for Diabetes Management (Continous Monitoring And Control of Hypoglycemia: The COACH Study)
Principal Investigators: Amy Criego, MD; Anders Carlson, MD
Study Sponsor: Dexcom, Inc.
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to find out how using a CGM (Continuous Glucose Monitor) works for making diabetes treatment decisions, instead of using finger-stick testing of blood sugars. A continuous glucose monitor is a device that measures glucose levels every 5 minutes.
Inclusion Criteria:
The study is accepting males and females ages 2 years and older who:
– Have type 1 or type 2 diabetes
– Have not used a personal CGM in the past 12 months and are willing to use CGM during the study
– Meet other study specific requirements
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Dexcom, Inc.
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to see if blood glucose control is different using a continuous glucose monitor (CGM) compared to those who use a blood glucose meter, for people who have type 2 diabetes and are taking insulin injections every day. A CGM is a device that measures glucose levels every 5 minutes. The study will be using the Dexcom G6 CGM system. The study team will work with participants’ usual health care providers, giving information about their study glucose and options for improving their diabetes management.
Inclusion Criteria:
The study is accepting men and women ages 30 or older who:
– Have type 2 diabetes and are taking long-acting insulin injections every day
– Have an A1C of 8.0-11.5%
– Have not used a personal continuous glucose monitor (CGM) in the past 6 months and are willing to use a CGM during the study
– Have a smart phone and willing to use a phone app
– Meet other study specific requirements
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
